Landipirdine

DB16214InvestigationalSmall molecule

Landipirdine is under investigation in clinical trial NCT02258152 (SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)).

Formula / weight: C₁₈H₁₉FN₂O₃S · 362.42 g/mol (avg)
Code names: R0-5025181 · R0-5025181-000 · SYN-120

Resolves to

Compound

UNIIJ0NX985GDICAS1000308-25-7ChEMBLCHEMBL1082508

Structure

InChIKeyMTTHRRVVGMPYQG-ZDUSSCGKSA-NSMILESNC(=O)NC[C@@H]1CCCC2=CC(=CC=C12)S(=O)(=O)C1=CC(F)=CC=C1

Targets

P28223HTR2AP50406HTR6

What you can answer from here — as of April 23, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Landipirdine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account